1. PI3K/AKT signaling pathway and cancer: an updated review;Martini;Ann. Med.,2014
2. Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma;Molina;Cancer,2012
3. Efficacy of PI3K/AKT/mTOR pathway inhibitors for the treatment of advanced solid cancers: a literature-based meta-analysis of 46 randomised control trials;Li;PloS One,2018
4. Broad spectrum anticancer activity of myo-inositol and inositol hexakisphosphate;Bizzarri;Internet J. Endocrinol.,2016
5. Advances with phospholipid signalling as a target for anticancer drug development;Powis;Acta Biochim. Pol.,1995